Edition:
India

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

103.70USD
19 Sep 2019
Change (% chg)

$0.72 (+0.70%)
Prev Close
$102.98
Open
$103.65
Day's High
$103.89
Day's Low
$103.27
Volume
33,857
Avg. Vol
718,856
52-wk High
$141.81
52-wk Low
$92.57

Latest Key Developments (Source: Significant Developments)

Alexion And Bridgebio Announce Japanese License Agreement For Eidos' Transthyretin Amyloidosis Investigational Medicine
Monday, 9 Sep 2019 

Sept 9 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION AND BRIDGEBIO ANNOUNCE JAPANESE LICENSE AGREEMENT FOR EIDOS’ TRANSTHYRETIN AMYLOIDOSIS (ATTR) INVESTIGATIONAL MEDICINE.ALEXION PHARMACEUTICALS INC - EIDOS GRANTS ALEXION EXCLUSIVE LICENSE TO DEVELOP AND COMMERCIALIZE AG10 IN JAPAN.ALEXION PHARMACEUTICALS - EIDOS TO RECEIVE UPFRONT PAYMENT OF $25 MILLION AND EQUITY INVESTMENT OF $25 MILLION.ALEXION PHARMACEUTICALS INC - PHASE 3 STUDY OF AG10 IN ATTR CARDIOMYOPATHY UNDERWAY IN U.S. & EUROPE.ALEXION PHARMACEUTICALS INC - PHASE 3 TRIAL IN ATTR POLYNEUROPATHY PLANNED TO INITIATE IN SECOND HALF OF 2019.  Full Article

Alexion Pharmaceuticals Says European Patent Office To Not Grant Co Patent Application Relating To Pharmaceutical Composition Of Soliris
Friday, 6 Sep 2019 

Sept 5 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION PHARMACEUTICALS - EUROPEAN PATENT OFFICE TO NOT GRANT CO PATENT APPLICATION RELATING TO PHARMACEUTICAL COMPOSITION OF SOLIRIS (ECULIZUMAB).ALEXION PHARMACEUTICALS INC - WILL EVALUATE OPTION TO APPEAL THE EUROPEAN PATENT OFFICE’S DECISION.ALEXION PHARMA - EUROPEAN PATENT OFFICE TO NOT GRANT CO PATENT APPLICATION RELATING TO PHARMACEUTICAL COMPOSITION OF MATTER OF SOLIRIS (ECULIZUMAB).  Full Article

Alexion Pharmaceuticals Receives Marketing Authorization From EC For Ultomiris For Adults With PNH
Wednesday, 3 Jul 2019 

July 3 (Reuters) - Alexion Pharmaceuticals Inc ::ULTOMIRIS® (RAVULIZUMAB) RECEIVES MARKETING AUTHORIZATION FROM EUROPEAN COMMISSION FOR ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH).ALEXION PHARMACEUTICALS - EC APPROVAL BASED ON RESULTS FROM TWO PHASE 3 STUDIES.  Full Article

FDA Grants Approval Of Soliris, A Treatment For Neuromyelitis Optica Spectrum Disorder, To Alexion Pharmaceuticals
Thursday, 27 Jun 2019 

June 27 (Reuters) - FDA::FDA APPROVES FIRST TREATMENT FOR NEUROMYELITIS OPTICA SPECTRUM DISORDER, A RARE AUTOIMMUNE DISEASE OF THE CENTRAL NERVOUS SYSTEM.FDA SAYS GRANTED APPROVAL OF SOLIRIS TO ALEXION PHARMACEUTICALS.FDA SAYS SOLIRIS HAS A BOXED WARNING THAT LIFE-THREATENING AND FATAL MENINGOCOCCAL INFECTIONS HAVE OCCURRED IN PATIENTS TREATED WITH SOLIRIS.  Full Article

Alexion Says FDA Accepted sBLA For Ultomiris Under Priority Review
Thursday, 20 Jun 2019 

June 20 (Reuters) - Alexion Pharmaceuticals Inc ::U.S. FDA ACCEPTS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION (SBLA) FOR ULTOMIRIS® (RAVULIZUMAB-CWVZ) UNDER PRIORITY REVIEW FOR THE TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS).ALEXION PHARMACEUTICALS INC - FDA SETS TARGET ACTION DATE OF OCTOBER 19, 2019.  Full Article

Alexion Pharma Reports Positive Extension Data From Late-Stage Study of Ultomiris In Patients With Paroxysmal Nocturnal Hemoglobinuria
Friday, 14 Jun 2019 

June 14 (Reuters) - Alexion Pharmaceuticals Inc ::POSITIVE PHASE 3 EXTENSION DATA FOR ULTOMIRIS® (RAVULIZUMAB) IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PRESENTED AT EUROPEAN HEMATOLOGY ASSOCIATION (EHA) CONGRESS.ALEXION PHARMACEUTICALS INC - ULTOMIRIS DEMONSTRATED CONSISTENT EFFICACY AND SAFETY THROUGH 52 WEEKS.ALEXION PHARMACEUTICALS - SUSTAINED EFFICACY OF ULTOMIRIS WAS OBSERVED ON CO-PRIMARY ENDPOINTS OF TRANSFUSION AVOIDANCE & NORMALIZATION OF LDH LEVELS.ALEXION PHARMACEUTICALS - MOST COMMON ADVERSE EVENTS OCCURRED LESS FREQUENTLY IN EXTENSION PHASE THAN DURING INITIAL TREATMENT PHASE FOR ULTOMIRIS.ALEXION PHARMACEUTICALS - SUSTAINED EFFICACY OF ULTOMIRIS WAS OBSERVED ON SECONDARY ENDPOINTS OF LDH LEVEL REDUCTION AND BREAKTHROUGH HEMOLYSIS.  Full Article

Zealand Pharma And Alexion Announce Collaboration
Wednesday, 20 Mar 2019 

March 20 (Reuters) - Zealand Pharma A/S ::REG-ALEXION AND ZEALAND PHARMA ANNOUNCE COLLABORATION TO DISCOVER AND DEVELOP PEPTIDE THERAPIES FOR COMPLEMENT-MEDIATED DISEASES.ZEALAND PHARMA TO RECEIVE UPFRONT PAYMENT OF $25 MILLION AND EQUITY INVESTMENT OF $15 MILLION.ZEALAND PHARMA WITH POTENTIAL FOR ADDITIONAL MILESTONE-DEPENDENT AND ROYALTY PAYMENTS.AGREEMENT PROVIDES POTENTIAL FOR DEVELOPMENT-RELATED MILESTONES OF UP TO $115 MILLION.AGREEMENT PROVIDES AS WELL AS UP TO $495 MILLION IN SALES-RELATED MILESTONES AND POTENTIAL FOR HIGH SINGLE- TO LOW DOUBLE-DIGIT ROYALTY PAYMENTS.  Full Article

Alexion And Affibody Announce Partnership To Co-Develop Anti-FcRn Affibody Molecule
Wednesday, 20 Mar 2019 

March 20 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION AND AFFIBODY ANNOUNCE PARTNERSHIP TO CO-DEVELOP ANTI-FCRN AFFIBODY® MOLECULE.ALEXION PHARMACEUTICALS INC - AGREEMENT PROVIDES OPPORTUNITY TO EXPAND ALEXION'S CLINICAL-STAGE ANTI-FCRN PORTFOLIO WITH ABY-039.ALEXION - AFFIBODY TO RECEIVE $25 MILLION UPFRONT PAYMENT WITH POTENTIAL FOR ADDITIONAL MILESTONE-DEPENDENT AND ROYALTY PAYMENTS.ALEXION - POTENTIAL FOR ADDITIONAL MILESTONE PAYMENTS OF UP TO $625 MILLION AND TIERED LOW DOUBLE-DIGIT ROYALTY PAYMENTS AS PART OF DEAL.ALEXION - CO WILL LEAD JOINT CLINICAL DEVELOPMENT OF ABY-039 AND COMMERCIALIZATION ACTIVITIES.ALEXION - AFFIBODY HAS OPTION TO CO-PROMOTE ABY-039 IN U.S. AND WILL LEAD CLINICAL DEVELOPMENT FOR AN UNDISCLOSED INDICATION.  Full Article

Alexion Opposes Claims Against Co Filed By Chugai Pharmaceutical
Friday, 16 Nov 2018 

Nov 16 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>::ALEXION - RESPONDING TO COMPLAINT FILED AGAINST CO BY CHUGAI PHARMACEUTICAL, CO TO OPPOSE CLAIMS & TO PROCEED WITH BUSINESS PLANS FOR ALXN1210.  Full Article

Temasek Holdings (Private) Ltd Dissolves Share Stake In Walt Disney, Amgen and Biogen
Wednesday, 14 Nov 2018 

Nov 14 (Reuters) - Temasek Holdings (Private) Ltd::TEMASEK HOLDINGS (PRIVATE) LTD DISSOLVES SHARE STAKE IN WALT DISNEY CO - SEC FILING.TEMASEK HOLDINGS (PRIVATE) LTD DISSOLVES SHARE STAKE IN AMGEN INC.TEMASEK HOLDINGS (PRIVATE) LTD DISSOLVES SHARE STAKE IN BIOGEN INC.TEMASEK HOLDINGS (PRIVATE) LTD CUTS SHARE STAKE IN ALEXION PHARMACEUTICALS INC BY 18.5 PERCENT TO 1.2 MILLION SHARES.TEMASEK HOLDINGS (PRIVATE) LTD REPORTS SHARE STAKE OF 4.5 MILLION SHARES IN FARFETCH LTD.TEMASEK HOLDINGS (PRIVATE) LTD - CHANGE IN HOLDINGS ARE AS OF SEPTEMBER 30, 2018 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF JUNE 30, 2018.  Full Article

Photo

Patent court to review Alexion's Soliris patents on Amgen challenge

The U.S. patent office will review patents on Alexion Pharmaceuticals Inc's blood disorder treatment Soliris, after Amgen Inc challenged them, court filings showed on Friday.